Azenta (AZTA) 10-Q 10 Feb 25 2025 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Dec. 31, 2024	Feb. 03, 2025
Document Information [Line Items]
Entity Central Index Key	0000933974
Entity Registrant Name	Azenta, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	000-25434
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	200 Summit Drive, 6th Floor
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	888
Local Phone Number	229-3682
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,695,591

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Current assets
Cash and cash equivalents of continuing operations	$ 377,494	$ 280,030
Short-term marketable securities	85,951	151,162
Accounts receivable, net of allowance for expected credit losses ($5,182 and $5,349, respectively)	155,038	156,273
Inventories	81,006	78,923
Short-term restricted cash	2,080	2,069
Prepaid expenses and other current assets	72,140	75,456
Current assets held for sale	72,573	88,894
Total current assets	846,282	832,807
Property, plant and equipment, net	149,666	155,622
Long-term marketable securities	27,433	49,454
Long-term deferred tax assets	627	837
Operating lease right-of-use assets	60,460	60,406
Goodwill	672,906	691,409
Intangibles assets, net	115,822	125,042
Other assets	9,410	10,670
Noncurrent assets held for sale	158,604	173,794
Total assets	2,041,210	2,100,041
Current liabilities
Accounts payable	31,740	33,344
Deferred revenue	41,018	30,493
Accrued warranty and retrofit costs	4,973	5,213
Accrued compensation and benefits	28,405	27,785
Accrued customer deposits	26,833	22,324
Accrued income taxes payable	6,931	9,266
Accrued expenses and other current liabilities	38,965	46,364
Current liabilities held for sale	23,602	30,050
Total current liabilities	202,467	204,839
Long-term tax reserves	408	398
Long-term deferred tax liabilities	18,668	18,084
Long-term operating lease liabilities	54,341	56,683
Other long-term liabilities	8,229	8,874
Noncurrent liabilities held for sale	38,131	42,196
Total liabilities	322,244	331,074
Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value - 125,000,000 shares authorized, 59,153,757 shares issued and 45,691,888 shares outstanding at December 31, 2024; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024	592	590
Additional paid-in capital	511,068	505,958
Accumulated other comprehensive loss	(55,237)	(13,464)
Treasury stock, at cost - 13,461,869 shares at December 31, 2024 and September 30, 2024	(200,956)	(200,956)
Retained earnings	1,463,499	1,476,839
Total stockholders' equity	1,718,966	1,768,967
Total liabilities and stockholders' equity	$ 2,041,210	$ 2,100,041

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Allowance for Doubtful Accounts Receivable, Current	$ 5,182	$ 5,349
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	125,000,000	125,000,000
Common stock, issued (in shares)	59,153,757	59,031,953
Common stock, outstanding (in shares)	45,691,888	45,570,084
Treasury stock, shares (in shares)	13,461,869	13,461,869

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue
Total revenue	$ 147,510	$ 141,725
Cost of revenue
Total cost of revenue	78,839	79,982
Gross profit	68,671	61,743
Operating expenses
Research and development	6,380	7,313
Selling, general and administrative	73,213	69,889
Provisions	431	786
Total operating expenses	80,024	77,988
Operating loss	(11,353)	(16,245)
Other income
Interest income, net	4,298	9,955
Other income, net	1,203	518
Loss before income taxes	(5,852)	(5,772)
Income tax expense	3,569	1,420
Loss from continuing operations	(9,421)	(7,192)
Loss from discontinued operations, net of tax	(3,919)	(8,532)
Net loss	$ (13,340)	$ (15,724)
Basic net loss per share:
Loss from continuing operations (in dollars per share)	$ (0.21)	$ (0.13)
Loss from discontinued operations, net of tax (in dollars per share)	(0.09)	(0.15)
Basic net loss per share (in dollars per share)	(0.29)	(0.28)
Diluted net loss per share:
Loss from continuing operations (in dollars per share)	(0.21)	(0.13)
Loss from discontinued operations, net of tax (in dollars per share)	(0.09)	(0.15)
Diluted net loss per share (in dollars per share)	$ (0.29)	$ (0.28)
Weighted average shares used in computing net loss per share:
Basic (in shares)	45,626	56,709
Diluted (in shares)	45,626	56,709
Product [Member]
Revenue
Total revenue	$ 43,827	$ 43,707
Cost of revenue
Total cost of revenue	25,334	26,783
Service [Member]
Revenue
Total revenue	103,683	98,018
Cost of revenue
Total cost of revenue	$ 53,505	$ 53,199

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Net loss	$ (13,340)	$ (15,724)
Other comprehensive income (loss), net of tax
Net investment hedge currency translation adjustment, net of tax effects of $0 and $4,576 for the three months ended December 31, 2024 and 2023, respectively	5,412	(13,368)
Foreign currency translation adjustments	(47,298)	46,494
Changes in unrealized losses on marketable securities, net of tax effects of $0 and $864 for the three months ended December 31, 2024 and 2023, respectively	163	2,524
Actuarial loss on pension plans, net of tax effects of $17 and $2 during the three months ended December 31, 2024 and 2023, respectively	(50)	(8)
Total other comprehensive income (loss), net of tax	(41,773)	35,642
Comprehensive income (loss)	$ (55,113)	$ 19,918

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	$ 0	$ 4,576
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax	0	864
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax	$ 17	$ 2

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (13,340)	$ (15,724)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	18,100	21,866
Inventory write-downs and other asset write-offs	1,470	0
Stock-based compensation	5,112	3,202
Amortization and accretion on marketable securities	(541)	(704)
Deferred income taxes	457	(7,317)
(Gain) loss on disposals of property, plant and equipment	(8)	266
Changes in operating assets and liabilities:
Accounts receivable	4,850	2,830
Inventories	(4,646)	4,929
Accounts payable	(2,602)	2,442
Deferred revenue	10,462	(321)
Accrued warranty and retrofit costs	174	(554)
Accrued compensation and tax withholdings	650	(979)
Accrued restructuring costs	(566)	(90)
Other assets and liabilities	11,056	3,910
Net cash provided by operating activities	30,628	13,756
Cash flows from investing activities
Purchases of property, plant and equipment	(8,580)	(11,291)
Purchases of marketable securities	(40,754)	0
Sales and maturities of marketable securities	125,590	110,316
Net cash provided by investing activities	76,256	99,025
Cash flows from financing activities
Payments of finance leases	(215)	(198)
Withholding tax payments on net share settlements on equity awards	0	(2)
Share repurchases	0	(112,953)
Excise tax payment for settled share repurchases	(4,911)	0
Net cash used in financing activities	(5,126)	(113,153)
Effects of exchange rate changes on cash, cash equivalents and restricted cash	(8,311)	24,548
Net increase in cash, cash equivalents and restricted cash	93,447	24,176
Cash, cash equivalents and restricted cash, beginning of period	320,990	684,045
Cash, cash equivalents and restricted cash, end of period	414,437	708,221
Supplemental disclosures:
Cash paid / (received) for income taxes, net	(6,148)	2,599
Purchases of property, plant and equipment included in accounts payable and accrued expenses	$ 3,249	$ 2,164

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - Reconciliation of Cash - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Cash and cash equivalents of continuing operations	$ 377,494	$ 280,030
Cash included in current assets held for sale	26,544	30,899
Short-term restricted cash	2,080	2,069
Long-term restricted cash included in other assets	8,319	7,992
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 414,437	$ 320,990

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Open Market Repurchases [Member] Common Stock Outstanding [Member]	Open Market Repurchases [Member] Additional Paid-in Capital [Member]	Open Market Repurchases [Member] AOCI Attributable to Parent [Member]	Open Market Repurchases [Member] Retained Earnings [Member]	Open Market Repurchases [Member] Treasury Stock, Common [Member]	Open Market Repurchases [Member]	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Sep. 30, 2023							71,294,247
Balance at Sep. 30, 2023							$ 713	$ 1,156,160	$ (62,426)	$ 1,641,009	$ (200,956)	$ 2,534,500
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)							144,894
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes							$ 2	(2)	0	0	0	0
Stock-based compensation							0	3,202	0	0	0	3,202
Net loss							0	0	0	(15,724)	0	(15,724)
Net investment hedge currency translation adjustment, net of tax							0	0	(13,368)	0	0	(13,368)
Foreign currency translation adjustments							0	0	46,494	0	0	46,494
Changes in unrealized losses on marketable securities, net of tax							0	0	2,524	0	0	2,524
Actuarial loss on pension plans, net of tax							$ 0	0	(8)	0	0	(8)
Balance (in shares) at Dec. 31, 2023							69,180,281
Balance at Dec. 31, 2023							$ 692	1,045,427	(26,784)	1,625,285	(200,956)	2,443,664
Shares repurchases (in shares)	(2,258,860)
Share repurchases		$ 0	$ 0	$ 0	$ (113,956)	$ (113,956)
Retirement of treasury shares							$ (23)	(113,933)	0	0	113,956	0
Balance (in shares) at Sep. 30, 2024							59,031,953
Balance at Sep. 30, 2024							$ 590	505,958	(13,464)	1,476,839	(200,956)	1,768,967
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)							121,804
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes							$ 2	(2)	0	0	0	0
Stock-based compensation							0	5,112	0	0	0	5,112
Net loss							0	0	0	(13,340)	0	(13,340)
Net investment hedge currency translation adjustment, net of tax							0	0	5,412	0	0	5,412
Foreign currency translation adjustments							0	0	(47,298)	0	0	(47,298)
Changes in unrealized losses on marketable securities, net of tax							0	0	163	0	0	163
Actuarial loss on pension plans, net of tax							$ 0	0	(50)	0	0	(50)
Balance (in shares) at Dec. 31, 2024							59,153,757
Balance at Dec. 31, 2024							$ 592	$ 511,068	$ (55,237)	$ 1,463,499	$ (200,956)	$ 1,718,966

Note 1 - Nature of Operations

Note 1 - Nature of Operations	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Nature of Operations [Text Block]	1. Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company entered the life sciences market in 2011 , Discontinued Operations During the first 2025, The Company determined that the B Medical Systems segment met the “held for sale” criteria and “discontinued operations” criteria in accordance with Financial Accounting Standard Boards (“FASB”) Accounting Standards Codification (“ASC”) 205, Presentation of Financial Statements 205” November 12, 2024. 3, Discontinued Operations 205. Also included in discontinued operations is a loss contingency related to the Company's sale of the semiconductor automation business in February 2022. December 31, 2024.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Principles of Consolidation and Basis of Presentation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying year-end balance sheet as of September 30, 2024 not Certain information and disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10 September 30, 2024 November 27, 2024 ( “2024 10 Revisions to Previously Issued Financial Statements and Financial Information As previously disclosed in the 2024 10 2024 September 30, 2023 March 31, 2023, June 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 . September 30, 2023 June 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024. March 31, 2023, June 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 21, Revision of Previously Issued Unaudited Quarterly Information 8 2024 10 The effect on the Condensed Consolidated Statement of Cash Flows for the interim period ended December 31, 2023 Three months ended December 31, 2023 As Reported Adjustments As Revised Cash flows from operating activities Inventories $ 4,542 $ 387 $ 4,929 Accounts payable 3,457 (1,015 ) 2,442 Other assets and liabilities 15,957 (12,047 ) 3,910 Net cash provided by operating activities $ 26,431 $ (12,675 ) $ 13,756 Cash flows from investing activities Purchase of property, plant and equipment $ (11,919 ) $ 628 $ (11,291 ) Net cash provided by investing activities $ 98,397 $ 628 $ 99,025 Effects of exchange rate changes on cash and cash equivalents $ 12,501 $ 12,047 $ 24,548 Supplemental disclosures: Purchases of property, plant and equipment included in accounts payable and accrued expenses $ — $ 2,164 $ 2,164 The Company assessed the effect of the errors on prior periods under the guidance of Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 99, 250 , Accounting Changes and Error Corrections not no Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may may Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income” in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement gains were$0.5 million three December 31, 2024 2023 Recently Issued Accounting Pronouncements In November 2023, 2023 07, Segment Reporting (Topic 280 December 15, 2023, December 15, 2024, In December 2023, 2023 09, Income Taxes (Topic 740 Improvements to Income Tax Disclosures December 15, 2024, not 2026. In March 2024, No. 33 11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors 2026, 2027, 1 2 April 2024, December 31, 2024. In 2021, 2” 15% 2 January 1, 2024 January 1, 2025. not not €750 twelve In November 2024, 2024 03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses. December 15, 2026, Other For further information regarding the Company’s significant accounting policies, please refer to Note 2, Summary of Significant Accounting Policies 8 2024 10 no three December 31, 2024

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3. Plan to Sell B Medical Systems Business During the first 2025, November 2025. The Company determined that the B Medical Systems segment met the “held for sale” criteria and “discontinued operations” criteria in accordance with FASB ASC 205 November 12, 2024. 205. The following table presents the financial results of the B Medical Systems segment, included within discontinued operations (in thousands): Three Months Ended December 31, 2024 2023 Revenue Products $ 14,288 $ 9,686 Services 3,303 2,906 Total revenue 17,591 12,592 Cost of revenue Products 11,422 10,056 Services 3,306 2,768 Total cost of revenue 14,728 12,824 Gross profit 2,863 (232 ) Operating expenses Research and development 1,635 1,180 Selling, general and administrative 6,187 8,687 Restructuring charges 314 334 Total operating expenses 8,136 10,201 Operating loss (5,273 ) (10,433 ) Interest income, net 5 127 Other income, net 530 164 Loss before income taxes (4,738 ) (10,142 ) Income tax benefit (819 ) (1,610 ) Loss from discontinued operations, net of tax $ (3,919 ) $ (8,532 ) The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the B Medical Systems segment that are included in the Condensed Consolidated Statements of Cash Flows (in thousands): Three Months Ended December 31, 2024 2023 Depreciation and amortization $ 3,846 $ 7,219 Capital expenditures 757 1,246 The carrying value of the assets and liabilities of the discontinued operations with respect to the B Medical Systems segment reflected as “held for sale” on the Condensed Consolidated Balance Sheets as of December 31, 2024 September 30, 2024 December 31, 2024 September 30, 2024 Assets Cash and cash equivalents $ 26,544 $ 30,899 Accounts receivable, net 8,010 16,438 Inventories 33,361 36,333 Prepaid expenses and other current assets 4,658 5,224 Current assets held for sale $ 72,573 $ 88,894 Property, plant and equipment, net $ 43,681 $ 47,032 Intangibles, net 111,569 122,988 Other assets 3,354 3,774 Noncurrent assets held for sale $ 158,604 $ 173,794 Liabilities Accounts payable $ 9,148 $ 11,089 Deferred revenue 598 1,485 Accrued warranty and retrofit costs 4,764 4,916 Accrued compensation and benefits 2,303 2,929 Accrued income taxes 1,840 4,012 Accrued expenses and other current liabilities 4,949 5,619 Current liabilities held for sale $ 23,602 $ 30,050 Long-term deferred tax liabilities 32,802 36,093 Long-term operating lease liabilities 1,993 2,109 Other long-term liabilities 3,336 3,994 Noncurrent liabilities held for sale $ 38,131 $ 42,196 Disposition of Semiconductor Business On February 1, 2022, July 1, 2019, may fourth 2018. third 2020, “2020 January 2023, third “2023 In April 2023, 2023 third 2023, 2023 one 2023 2020 2023 third 2023. 2020 December 31, 2024. The Company had been informed that Edwards sought recovery for the 2020 first 2025, not not In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no

Note 4 - Marketable Securities

Note 4 - Marketable Securities	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	4. The Company had sales and maturities of marketable securities of $125.6 million and million three December 31, 2024 2023 ere three December 31, 2024 2023 The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized gains (losses) on the short-term and long-term marketable securities as of December 31, 2024 September 30, 2024 ​ ​ Gross Gross ​ ​ Amortized Unrealized Unrealized ​ ​ Cost Losses Gains Fair Value December 31, 2024: U.S. Treasury securities and obligations of U.S. government agencies $ 68,189 $ (83 ) $ 9 $ 68,115 Bank certificates of deposit 2,229 (6 ) — 2,223 Corporate securities 42,634 (116 ) — 42,518 Municipal securities 528 — — 528 ​ $ 113,580 $ (205 ) $ 9 $ 113,384 September 30, 2024: U.S. Treasury securities and obligations of U.S. government agencies $ 118,159 $ (119 ) $ 51 $ 118,091 Bank certificates of deposit 5,212 (13 ) 1 5,200 Corporate securities 77,580 (255 ) — 77,325 ​ $ 200,951 $ (387 ) $ 52 $ 200,616 The amortized cost and fair value of the marketable securities by contractual maturities as of December 31, 2024 ​ Amortized ​ ​ Cost Fair Value Due in one year or less $ 86,122 $ 85,951 Due after one year through five years 23,880 23,855 Due after ten years 3,578 3,578 Total marketable securities $ 113,580 $ 113,384 Expected maturities could differ from contractual maturities because the security issuers may Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. The Company does not ​

Note 5 - Derivative Instruments

Note 5 - Derivative Instruments	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	5. The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. Net gains and losses related to foreign exchange contracts are recorded as a component of “Other income, net” in the Condensed Consolidated Statements of Operations and were as follows for the three December 31, 2024 2023 ​ Three Months Ended ​ December 31, ​ 2024 2023 Realized gains (losses) on derivatives not designated as hedging instruments $ 1,195 $ (1,239 ) The notional amounts of the Company’s derivative instruments as of December 31, 2024 September 30, 2024 ​ ​ December 31, September 30, ​ Hedge Designation 2024 2024 ​ ​ ​ ​ Cross-currency swap Net Investment Hedge $ 75,978 $ 75,978 Foreign exchange contracts Undesignated 36,573 60,101 The fair values of the foreign exchange contracts are recorded in the Condensed Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 2, Summary of Significant Accounting Policies 8 2024 10 12, Fair Value Measurements Hedging Activities On February 1, 2023, €400.0 one February 1, 2024, €400 On February 1, 2024, €70.0 one February 3, 2025. Following the three December 31, 2024, February 3, 2025, €70.0 On February 3, 2025, €250.0 one February 2, 2026. The cross-currency swaps were recorded as a derivative asset within “Prepaid expenses and other current assets” as of December 31, 2024 September 30, 2024 The cross-currency swap is marked to market at each reporting period, representing the fair value of the cross-currency swap, any changes in fair value are recognized as a component of “Accumulated other comprehensive loss” in the Condensed Consolidated Balance Sheets. The cross-currency swap is classified within Level 2 2, Summary of Significant Accounting Policies 8 2024 10 12, Fair Value Measurements Interest earned on the cross-currency swap is recorded within “Interest income, net” in the Condensed Consolidated Statements of Operations. For the three December 31, 2024 2023 million

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. The Company conducts an impairment assessment annually on April 1, October 1, 2023 15, Segment and Geographic Information The following table sets forth the changes in the carrying amount of goodwill by operating and reportable segment since September 30, 2024 ( ​ Sample ​ Management Solutions Multiomics Total Balance - October 1, 2024 $ 494,649 $ 196,760 $ 691,409 Currency translation adjustments (18,503 ) — (18,503 ) Balance - December 31, 2024 $ 476,146 $ 196,760 $ 672,906 The components of the Company’s identifiable intangible assets as of December 31, 2024 September 30, 2024 ​ December 31, 2024 September 30, 2024 ​ ​ Accumulated Net Book ​ Accumulated Net Book ​ Cost Amortization Value Cost Amortization Value Patents $ 1,220 $ 1,220 $ — $ 1,227 $ 1,227 $ — Completed technology 106,665 56,034 50,631 109,949 55,191 54,758 Trademarks and trade names 705 214 491 726 195 531 Customer relationships 243,930 179,230 64,700 248,036 178,283 69,753 Total $ 352,520 $ 236,698 $ 115,822 $ 359,938 $ 234,896 $ 125,042 Amortization expenses for intangible assets were $6.1 million and $7.2 million, respectively, for the three December 31, 2024 2023 Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2025 five Remainder of fiscal year 2025 $ 18,243 2026 21,697 2027 17,290 2028 14,459 2029 11,854 2030 10,336

Note 7 - Restructuring

Note 7 - Restructuring	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	7. 2024 In the second 2024, 2026. not not The majority of the restructuring expenses associated with the initiatives described above for the three December 31, 2024 three December 31, 2024 2023 In the second third 2023, first 2024 . The restructuring expenses associated with the 2023 three December 31, 2023 The following table presents restructuring charges recognized for the three December 31, 2024 2023 ​ Three Months Ended December 31, ​ 2024 2023 Severance and related costs $ 320 $ 786 Other 111 — Total restructuring charges $ 431 $ 786 The following table presents activity in the severance and related costs accruals for the three December 31, 2024 2023 ​ Three Months Ended December 31, ​ 2024 2023 Balance at beginning of period $ 755 $ 665 Provisions 320 786 Payments (858 ) (696 ) Balance at end of period $ 217 $ 755

Note 8 - Supplementary Balance

Note 8 - Supplementary Balance Sheet Information	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	8. Inventories The following is a summary of inventories at December 31, 2024 September 30, 2024 ​ December 31, September 30, ​ 2024 2024 ​ Raw materials and purchased parts $ 39,916 $ 34,134 Work-in-process 7,585 8,402 Finished goods 33,505 36,387 Total inventories $ 81,006 $ 78,923 Inventory reserves were $7.2 million and $6.1 million, respectively, at December 31, 2024 September 30, 2024 Warranty and Retrofit Costs The following is a summary of product and warranty retrofit activity for the three December 31, 2024 2023 ​ Three Months Ended December 31, ​ 2024 2023 ​ ​ ​ Balance at beginning of period $ 5,213 $ 3,974 Accruals for warranties during the period 187 903 Costs incurred during the period (427 ) (320 ) Balance at end of period $ 4,973 $ 4,557

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Equity [Text Block]	9. Equity Share Repurchases On November 4, 2022 , “2022 three December 31, 2023, September 30, 2024 , 2022 2022 No no three December 31, 2024. Effective January 1, 2023 , one 2022 . three December 31, 2024, December 31, 2024. Accumulated Other Comprehensive Income (Loss) ​ The following is a summary of the components of accumulated other comprehensive income (loss), net of tax for the three December 31, 2024 2023 ​ ​ ​ Unrealized ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ on Available- Pension ​ ​ Currency for-Sale ​Gains (Losses) Liability ​ ​ Translation Securities on Derivative Adjustments ​ ​ Adjustments Net of tax Net of tax Net of tax Total Balance at September 30, 2023 $ (88,448 ) $ (5,135 ) $ 31,487 $ (330 ) $ (62,426 ) Other comprehensive income (loss) before reclassifications 46,494 2,524 (13,368 ) (35 ) 35,615 Amounts reclassified from accumulated other comprehensive loss — — — 27 27 Balance at December 31, 2023 $ (41,954 ) $ (2,611 ) $ 18,119 $ (338 ) $ (26,784 ) ​ ​ Unrealized ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ on Available- Pension ​ ​ Currency for-Sale ​Gains (Losses) Liability ​ ​ Translation Securities on Derivative Adjustments ​ ​ Adjustments Net of tax Net of tax Net of tax Total Balance at September 30, 2024 $ (34,170 ) $ (263 ) $ 21,468 $ (499 ) $ (13,464 ) Other comprehensive income (loss) before reclassifications (47,298 ) 163 5,412 (68 ) (41,791 ) Amounts reclassified from accumulated other comprehensive loss — — — 18 18 Balance at December 31, 2024 $ (81,468 ) $ (100 ) $ 26,880 $ (549 ) $ (55,237 ) As described in Note 2, Summary of Significant Accounting Policies 8 2024 10

Note 10 - Revenue From Contract

Note 10 - Revenue From Contracts with Customers	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	10. Disaggregated Revenue The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three December 31, 2024 2023 ​ Three months ended December 31, ​ 2024 2023 Significant Business Line ​ ​ Multiomics $ 66,297 $ 62,720 Core Products (1) 49,699 48,886 Sample Repository Services 31,514 30,119 Total revenue $ 147,510 $ 141,725 ( 1 Contract Balances Accounts Receivable, Net. not December 31, 2024 September 30, 2024, Contract Assets. not one December 31, 2024 September 30, 2024 three December 31, 2024 three December 31, 2023 December 31, 2024 September 30, 2024. Contract Liabilities. December 31, 2024 September 30, 2024 $21.6 three December 31, 2024 2023 . Remaining Performance Obligations. one December 31, 2024 ​ As of December 31, 2024 ​ Less than 1 Greater than 1 Total Remaining performance obligations $ 54,503 $ 30,053 $ 84,556

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. In accordance with the Company's 2020 may may 2020 The following table reflects the total stock-based compensation expense for continuing operations recorded during the three December 31, 2024 2023 ​ Three Months Ended December 31, ​ 2024 2023 Restricted stock units $ 4,615 $ 2,649 Employee stock purchase plan 257 352 Total stock-based compensation expense $ 4,872 $ 3,001 The Company recorded $0.2 million of stock-based compensation expense for discontinued operations during each of the three December 31, 2024 2023 Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the three December 31, 2024 ​ ​ Weighted ​ ​ Average ​ ​ Grant-Date ​ Shares Fair Value Outstanding as of September 30, 2024 764,111 $ 59.65 Granted 519,862 $ 47.14 Vested (121,804 ) $ 61.96 Forfeited (59,923 ) $ 94.75 Outstanding as of December 31, 2024 1,102,246 $ 51.21 Awards vested during the three December 31, 2024 three December 31, 2024 2023 As of December 31, 2024 Restricted stock units granted with performance goals may three December 31, 2024 2023 : ​ Three Months Ended December 31, ​ 2024 2023 Time-based restricted stock units 364,173 199,316 Performance-based restricted stock units 155,689 388,532 Total units 519,862 587,848 Restricted stock units granted during the three December 31, 2023 three December 31, 2024 Time-Based Restricted Stock Unit Grants Restricted stock units granted with a required service period typically have three one third Performance-Based Restricted Stock Unit Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Company's Board of Directors. The criteria for performance-based awards are weighted and have threshold, target, and maximum performance goals. Performance-based restricted stock unit awards granted allow participants to earn 100% of restricted stock units if the Company’s performance meets or exceeds its target goal for each applicable financial metric, and up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals are measured over a three third In November 2024, three three three no In October 2023, not November 2025. three December 31, 2024

Note 12 - Fair Value Measuremen

Note 12 - Fair Value Measurements	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	12. See Note 2, Summary of Significant Accounting Policies 8 2024 10 Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheets as of December 31, 2024 September 30, 2024 ​ As of December 31, 2024 Description Total Fair Value Level 1 Level 2 Level 3 Assets: Cash equivalents $ 207,170 $ 200,395 $ 6,775 $ — Available-for-sale securities 113,384 14,999 98,385 — Investment in equity securities 2,100 — — 2,100 Foreign exchange contracts 35 — 35 — Net investment hedge 3,497 — 3,497 — Total assets $ 326,186 $ 215,394 $ 108,692 $ 2,100 Liabilities: Foreign exchange contracts 122 — 122 — Total liabilities $ 122 $ — $ 122 $ — ​ As of September 30, 2024 Description Total Fair Value Level 1 Level 2 Level 3 Assets: Cash equivalents $ 157,990 $ 157,990 $ — $ — Available-for-sale securities 198,616 37,584 161,032 — Convertible debt securities 2,000 — — 2,000 Foreign exchange contracts 9 — 9 — Total assets $ 358,615 $ 195,574 $ 161,041 $ 2,000 Liabilities: Net investment hedge 1,915 — 1,915 — Foreign exchange contracts 213 $ — $ 213 $ — Total liabilities $ 2,128 $ — $ 2,128 $ — Cash Equivalents The Company considers all highly liquid interest-earning investments with a maturity of three three 1 2 not three Available-For-Sale Securities Available-for-sale securities primarily consist of highly rated corporate debt securities, and U.S. government backed securities, which are classified as Level 1. 2 not Convertible Debt Securities and Investment in Equity Securities In the third 2024, $2.1 During the first 2025, not 321, Investments - Equity Securities not December 31, 2024, 3 3 Foreign Exchange Contracts & Net Investment Hedge The Company’s foreign exchange contract assets and liabilities, and its net investment hedge assets are measured and reported at fair value using the market method valuation technique. The inputs to this technique utilize current foreign currency exchange forward market rates published by third not 2. Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis During the three December 31, 2024 2023, not

Note 13 - Income Taxes

Note 13 - Income Taxes	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. The Company recorded an income tax benefit of $3.6 million during the three December 31, 2024 three December 31, 2024 not not The Company recorded an income tax expense of $1.4 three December 31, 2023 three December 31, 2023 The Company evaluates the realizability of its deferred tax assets and assesses the need for a valuation allowance on a quarterly basis. The Company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and foreign tax authorities. The Company evaluates the profitability of its operations in each jurisdiction on a historic cumulative basis and on a forward-looking basis, while carefully considering carry-forward periods of tax attributes and ongoing tax planning strategies in assessing the need for the valuation allowance. The Company has generated U.S. pre-tax losses in recent years and provided a valuation allowance against U.S. deferred tax assets during fiscal year 2024. 2025 2025. The Company also maintains a valuation allowance against net deferred tax assets on certain foreign tax-paying components. The Company has not December 31, 2024. The Company maintains liabilities for unrecognized tax benefits based on its estimates and assumptions. The Company recognizes interest related to unrecognized tax benefits as a component of the income tax provision or benefit. The Company recognized minimal interest expense related to its unrecognized tax benefits during the three December 31, 2024. The Company is subject to U.S. federal, state, local and foreign income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company’s interpretation of applicable tax laws in the jurisdictions in which it files. In the normal course of business, the Company is subject to income tax audits in various global jurisdictions in which it operates. The years subject to examination vary for the United States and international jurisdictions, with the earliest tax year being 2018. not twelve

Note 14 - Net Loss Per Share

Note 14 - Net Loss Per Share	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	14. The calculations of basic and diluted net loss per share and basic and diluted weighted average shares outstanding are as follows for the three December 31, 2024 2023 ​ Three Months Ended ​ December 31, ​ 2024 2023 Loss from continuing operations $ (9,421 ) $ (7,192 ) Loss from discontinued operations, net of tax (3,919 ) (8,532 ) Net loss (13,340 ) (15,724 ) ​ ​ ​ Weighted average common shares outstanding used in computing basic loss per share 45,626 56,709 Weighted average common shares outstanding used in computing diluted loss per share 45,626 56,709 ​ ​ ​ Basic net loss per share: Loss from continuing operations $ (0.21 ) $ (0.13 ) Loss from discontinued operations, net of tax (0.09 ) (0.15 ) Basic net loss per share $ (0.29 ) $ (0.28 ) ​ ​ ​ Diluted net loss per share: Loss from continuing operations $ (0.21 ) $ (0.13 ) Loss from discontinued operations, net of tax (0.09 ) (0.15 ) Diluted net loss per share $ (0.29 ) $ (0.28 ) As a result of incurring a net loss from continuing operations for the three December 31, 2024 2023 three December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Time-based restricted stock units 87,117 62,983 Performance-based restricted stock units — 23,671 Employee stock purchase plan — 6,451 87,117 93,105

Note 15 - Segment and Geographi

Note 15 - Segment and Geographic Information	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s CODM. As of November 12, 2024, 205 The Company’s continuing operations includes the following operating and reportable segments: ​ ● Sample Management Solutions ● Multiomics ​ Management considers adjusted operating income (loss), which excludes charges related to amortization of intangible assets, transformation costs, restructuring charges, goodwill and intangible asset impairment, merger and acquisition costs and costs related to share repurchase, governance-related matters, and other unallocated corporate expenses, as the primary performance metric when evaluating each segment’s operations. The following is the summary of the financial information for the Company’s operating and reportable segments for the three December 31, 2024 2023 ​ Three Months Ended December 31, ​ 2024 2023 Revenue: ​ Sample Management Solutions $ 81,213 $ 79,005 Multiomics 66,297 62,720 Total revenue $ 147,510 $ 141,725 ​ ​ ​ Adjusted operating income (loss): ​ ​ Sample Management Solutions $ 2,317 $ (616 ) Multiomics (2,503 ) (3,263 ) Segment adjusted operating loss (186 ) (3,879 ) ​ ​ ​ Amortization of completed technology 1,500 1,856 Amortization of intangible assets other than completed technology 4,573 5,371 Transformation costs (1) 3,046 41 Restructuring charges 431 786 Merger and acquisition costs and costs related to share repurchase (2) 1,570 4,321 Other unallocated corporate expenses 47 (9 ) Total operating loss (11,353 ) (16,245 ) Interest income, net 4,298 9,955 Other income, net 1,203 518 Loss before income taxes $ (5,852 ) $ (5,772 ) ( 1 Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not 2024 one one third ( 2 Includes expenses related to governance-related matters. ​ The following is the summary of the asset information for the Company’s reportable segments as of December 31, 2024 September 30, 2024 Assets: December 31, 2024 September 30, 2024 Sample Management Solutions $ 840,580 $ 859,353 Multiomics 454,958 462,825 Total assets $ 1,295,538 $ 1,322,178 The following is a reconciliation of the segment assets to the corresponding amounts presented in the Condensed Consolidated Balance Sheets as of December 31, 2024 September 30, 2024 ​ December 31, September 30, ​ 2024 2024 Segment assets $ 1,295,538 $ 1,322,178 Cash and cash equivalents, restricted cash and marketable securities 501,277 490,707 Deferred tax assets 627 837 General corporate assets 12,591 23,631 Assets held for sale 231,177 262,688 Total assets $ 2,041,210 $ 2,100,041 Revenue from external customers is attributed to geographic areas based on locations in which the product is shipped. Net revenue by geographic area for the three December 31, 2024 2023 ​ Three Months Ended December 31, ​ 2024 2023 Geographic Location: ​ ​ United States $ 93,469 $ 90,127 China 14,888 14,898 United Kingdom 7,798 5,676 Rest of Europe 24,319 22,731 Asia Pacific/Other 7,036 8,293 Total revenue $ 147,510 $ 141,725 For the three December 31, 2024 2023 not 10% December 31, 2024 one 12% September 30, 2024, no 10%

Note 16 - Commitments and Conti

Note 16 - Commitments and Contingencies	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	16. Contingencies The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or, in certain instances, provide reasonable ranges of potential losses. The Company considers all claims on a quarterly basis and based on known facts assesses whether potential losses are considered reasonably possible, probable, and estimable. Based upon this assessment, the Company then evaluates disclosure requirements and whether to accrue for such claims in the Condensed Consolidated Financial Statements. At December 31, 2024 3, Discontinued Operations no no Tariff Matter With the assistance of a third first 2021, 2022 December 2021. July 2024, December 2021 July 2024. December 31, 2024, not third 2025. Purchase Commitments As of December 31, 2024

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation and Basis of Presentation The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and all entities where it has a controlling financial interest and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The accompanying year-end balance sheet as of September 30, 2024 not Certain information and disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10 September 30, 2024 November 27, 2024 ( “2024 10
Revision of Previously Issued Financial Statements for Error Correction Policy [Policy Text Block]	Revisions to Previously Issued Financial Statements and Financial Information As previously disclosed in the 2024 10 2024 September 30, 2023 March 31, 2023, June 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 . September 30, 2023 June 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024. March 31, 2023, June 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024 21, Revision of Previously Issued Unaudited Quarterly Information 8 2024 10 The effect on the Condensed Consolidated Statement of Cash Flows for the interim period ended December 31, 2023 Three months ended December 31, 2023 As Reported Adjustments As Revised Cash flows from operating activities Inventories $ 4,542 $ 387 $ 4,929 Accounts payable 3,457 (1,015 ) 2,442 Other assets and liabilities 15,957 (12,047 ) 3,910 Net cash provided by operating activities $ 26,431 $ (12,675 ) $ 13,756 Cash flows from investing activities Purchase of property, plant and equipment $ (11,919 ) $ 628 $ (11,291 ) Net cash provided by investing activities $ 98,397 $ 628 $ 99,025 Effects of exchange rate changes on cash and cash equivalents $ 12,501 $ 12,047 $ 24,548 Supplemental disclosures: Purchases of property, plant and equipment included in accounts payable and accrued expenses $ — $ 2,164 $ 2,164 The Company assessed the effect of the errors on prior periods under the guidance of Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 99, 250 , Accounting Changes and Error Corrections not no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect amounts reported in the financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may may
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income” in the Condensed Consolidated Statements of Operations. Net foreign currency transaction and remeasurement gains were$0.5 million three December 31, 2024 2023
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In November 2023, 2023 07, Segment Reporting (Topic 280 December 15, 2023, December 15, 2024, In December 2023, 2023 09, Income Taxes (Topic 740 Improvements to Income Tax Disclosures December 15, 2024, not 2026. In March 2024, No. 33 11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors 2026, 2027, 1 2 April 2024, December 31, 2024. In 2021, 2” 15% 2 January 1, 2024 January 1, 2025. not not €750 twelve In November 2024, 2024 03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses. December 15, 2026, Other For further information regarding the Company’s significant accounting policies, please refer to Note 2, Summary of Significant Accounting Policies 8 2024 10 no three December 31, 2024

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	Three months ended December 31, 2023 As Reported Adjustments As Revised Cash flows from operating activities Inventories $ 4,542 $ 387 $ 4,929 Accounts payable 3,457 (1,015 ) 2,442 Other assets and liabilities 15,957 (12,047 ) 3,910 Net cash provided by operating activities $ 26,431 $ (12,675 ) $ 13,756 Cash flows from investing activities Purchase of property, plant and equipment $ (11,919 ) $ 628 $ (11,291 ) Net cash provided by investing activities $ 98,397 $ 628 $ 99,025 Effects of exchange rate changes on cash and cash equivalents $ 12,501 $ 12,047 $ 24,548 Supplemental disclosures: Purchases of property, plant and equipment included in accounts payable and accrued expenses $ — $ 2,164 $ 2,164

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Three Months Ended December 31, 2024 2023 Revenue Products $ 14,288 $ 9,686 Services 3,303 2,906 Total revenue 17,591 12,592 Cost of revenue Products 11,422 10,056 Services 3,306 2,768 Total cost of revenue 14,728 12,824 Gross profit 2,863 (232 ) Operating expenses Research and development 1,635 1,180 Selling, general and administrative 6,187 8,687 Restructuring charges 314 334 Total operating expenses 8,136 10,201 Operating loss (5,273 ) (10,433 ) Interest income, net 5 127 Other income, net 530 164 Loss before income taxes (4,738 ) (10,142 ) Income tax benefit (819 ) (1,610 ) Loss from discontinued operations, net of tax $ (3,919 ) $ (8,532 )
Disposal Groups, Including Discontinued Operations, Statement of Cash Flows [Table Text Block]	Three Months Ended December 31, 2024 2023 Depreciation and amortization $ 3,846 $ 7,219 Capital expenditures 757 1,246
Schedule of Disposal Groups, Including Discontinued Operations, Balance Sheet [Table Text Block]	December 31, 2024 September 30, 2024 Assets Cash and cash equivalents $ 26,544 $ 30,899 Accounts receivable, net 8,010 16,438 Inventories 33,361 36,333 Prepaid expenses and other current assets 4,658 5,224 Current assets held for sale $ 72,573 $ 88,894 Property, plant and equipment, net $ 43,681 $ 47,032 Intangibles, net 111,569 122,988 Other assets 3,354 3,774 Noncurrent assets held for sale $ 158,604 $ 173,794 Liabilities Accounts payable $ 9,148 $ 11,089 Deferred revenue 598 1,485 Accrued warranty and retrofit costs 4,764 4,916 Accrued compensation and benefits 2,303 2,929 Accrued income taxes 1,840 4,012 Accrued expenses and other current liabilities 4,949 5,619 Current liabilities held for sale $ 23,602 $ 30,050 Long-term deferred tax liabilities 32,802 36,093 Long-term operating lease liabilities 1,993 2,109 Other long-term liabilities 3,336 3,994 Noncurrent liabilities held for sale $ 38,131 $ 42,196

Note 4 - Marketable Securities

Note 4 - Marketable Securities (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]	​ ​ Gross Gross ​ ​ Amortized Unrealized Unrealized ​ ​ Cost Losses Gains Fair Value December 31, 2024: U.S. Treasury securities and obligations of U.S. government agencies $ 68,189 $ (83 ) $ 9 $ 68,115 Bank certificates of deposit 2,229 (6 ) — 2,223 Corporate securities 42,634 (116 ) — 42,518 Municipal securities 528 — — 528 ​ $ 113,580 $ (205 ) $ 9 $ 113,384 September 30, 2024: U.S. Treasury securities and obligations of U.S. government agencies $ 118,159 $ (119 ) $ 51 $ 118,091 Bank certificates of deposit 5,212 (13 ) 1 5,200 Corporate securities 77,580 (255 ) — 77,325 ​ $ 200,951 $ (387 ) $ 52 $ 200,616
Investments Classified by Contractual Maturity Date [Table Text Block]	​ Amortized ​ ​ Cost Fair Value Due in one year or less $ 86,122 $ 85,951 Due after one year through five years 23,880 23,855 Due after ten years 3,578 3,578 Total marketable securities $ 113,580 $ 113,384

Note 5 - Derivative Instrumen_2

Note 5 - Derivative Instruments (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Derivative Instruments, Gain (Loss) [Table Text Block]	​ Three Months Ended ​ December 31, ​ 2024 2023 Realized gains (losses) on derivatives not designated as hedging instruments $ 1,195 $ (1,239 )
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	​ ​ December 31, September 30, ​ Hedge Designation 2024 2024 ​ ​ ​ ​ Cross-currency swap Net Investment Hedge $ 75,978 $ 75,978 Foreign exchange contracts Undesignated 36,573 60,101

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Goodwill [Table Text Block]	Sample ​ Management Solutions Multiomics Total Balance - October 1, 2024 $ 494,649 $ 196,760 $ 691,409 Currency translation adjustments (18,503 ) — (18,503 ) Balance - December 31, 2024 $ 476,146 $ 196,760 $ 672,906
Schedule of Finite-Lived Intangible Assets [Table Text Block]	​ December 31, 2024 September 30, 2024 ​ ​ Accumulated Net Book ​ Accumulated Net Book ​ Cost Amortization Value Cost Amortization Value Patents $ 1,220 $ 1,220 $ — $ 1,227 $ 1,227 $ — Completed technology 106,665 56,034 50,631 109,949 55,191 54,758 Trademarks and trade names 705 214 491 726 195 531 Customer relationships 243,930 179,230 64,700 248,036 178,283 69,753 Total $ 352,520 $ 236,698 $ 115,822 $ 359,938 $ 234,896 $ 125,042
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Remainder of fiscal year 2025 $ 18,243 2026 21,697 2027 17,290 2028 14,459 2029 11,854 2030 10,336

Note 7 - Restructuring (Tables)

Note 7 - Restructuring (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Restructuring and Related Costs [Table Text Block]	​ Three Months Ended December 31, ​ 2024 2023 Severance and related costs $ 320 $ 786 Other 111 — Total restructuring charges $ 431 $ 786
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	​ Three Months Ended December 31, ​ 2024 2023 Balance at beginning of period $ 755 $ 665 Provisions 320 786 Payments (858 ) (696 ) Balance at end of period $ 217 $ 755

Note 8 - Supplementary Balanc_2

Note 8 - Supplementary Balance Sheet Information (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	​ December 31, September 30, ​ 2024 2024 ​ Raw materials and purchased parts $ 39,916 $ 34,134 Work-in-process 7,585 8,402 Finished goods 33,505 36,387 Total inventories $ 81,006 $ 78,923
Schedule of Product Warranty Liability [Table Text Block]	​ Three Months Ended December 31, ​ 2024 2023 ​ ​ ​ Balance at beginning of period $ 5,213 $ 3,974 Accruals for warranties during the period 187 903 Costs incurred during the period (427 ) (320 ) Balance at end of period $ 4,973 $ 4,557

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	​ ​ Unrealized ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ on Available- Pension ​ ​ Currency for-Sale ​Gains (Losses) Liability ​ ​ Translation Securities on Derivative Adjustments ​ ​ Adjustments Net of tax Net of tax Net of tax Total Balance at September 30, 2023 $ (88,448 ) $ (5,135 ) $ 31,487 $ (330 ) $ (62,426 ) Other comprehensive income (loss) before reclassifications 46,494 2,524 (13,368 ) (35 ) 35,615 Amounts reclassified from accumulated other comprehensive loss — — — 27 27 Balance at December 31, 2023 $ (41,954 ) $ (2,611 ) $ 18,119 $ (338 ) $ (26,784 ) ​ ​ Unrealized ​ ​ ​ ​ ​ Gains (Losses) ​ ​ ​ ​ ​ on Available- Pension ​ ​ Currency for-Sale ​Gains (Losses) Liability ​ ​ Translation Securities on Derivative Adjustments ​ ​ Adjustments Net of tax Net of tax Net of tax Total Balance at September 30, 2024 $ (34,170 ) $ (263 ) $ 21,468 $ (499 ) $ (13,464 ) Other comprehensive income (loss) before reclassifications (47,298 ) 163 5,412 (68 ) (41,791 ) Amounts reclassified from accumulated other comprehensive loss — — — 18 18 Balance at December 31, 2024 $ (81,468 ) $ (100 ) $ 26,880 $ (549 ) $ (55,237 )

Note 10 - Revenue From Contra_2

Note 10 - Revenue From Contracts with Customers (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	​ Three months ended December 31, ​ 2024 2023 Significant Business Line ​ ​ Multiomics $ 66,297 $ 62,720 Core Products (1) 49,699 48,886 Sample Repository Services 31,514 30,119 Total revenue $ 147,510 $ 141,725
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	​ As of December 31, 2024 ​ Less than 1 Greater than 1 Total Remaining performance obligations $ 54,503 $ 30,053 $ 84,556

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]	​ Three Months Ended December 31, ​ 2024 2023 Restricted stock units $ 4,615 $ 2,649 Employee stock purchase plan 257 352 Total stock-based compensation expense $ 4,872 $ 3,001
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	​ ​ Weighted ​ ​ Average ​ ​ Grant-Date ​ Shares Fair Value Outstanding as of September 30, 2024 764,111 $ 59.65 Granted 519,862 $ 47.14 Vested (121,804 ) $ 61.96 Forfeited (59,923 ) $ 94.75 Outstanding as of December 31, 2024 1,102,246 $ 51.21 ​ Three Months Ended December 31, ​ 2024 2023 Time-based restricted stock units 364,173 199,316 Performance-based restricted stock units 155,689 388,532 Total units 519,862 587,848

Note 12 - Fair Value Measurem_2

Note 12 - Fair Value Measurements (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	​ As of December 31, 2024 Description Total Fair Value Level 1 Level 2 Level 3 Assets: Cash equivalents $ 207,170 $ 200,395 $ 6,775 $ — Available-for-sale securities 113,384 14,999 98,385 — Investment in equity securities 2,100 — — 2,100 Foreign exchange contracts 35 — 35 — Net investment hedge 3,497 — 3,497 — Total assets $ 326,186 $ 215,394 $ 108,692 $ 2,100 Liabilities: Foreign exchange contracts 122 — 122 — Total liabilities $ 122 $ — $ 122 $ — ​ As of September 30, 2024 Description Total Fair Value Level 1 Level 2 Level 3 Assets: Cash equivalents $ 157,990 $ 157,990 $ — $ — Available-for-sale securities 198,616 37,584 161,032 — Convertible debt securities 2,000 — — 2,000 Foreign exchange contracts 9 — 9 — Total assets $ 358,615 $ 195,574 $ 161,041 $ 2,000 Liabilities: Net investment hedge 1,915 — 1,915 — Foreign exchange contracts 213 $ — $ 213 $ — Total liabilities $ 2,128 $ — $ 2,128 $ —

Note 14 - Net Loss Per Share (T

Note 14 - Net Loss Per Share (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	​ Three Months Ended ​ December 31, ​ 2024 2023 Loss from continuing operations $ (9,421 ) $ (7,192 ) Loss from discontinued operations, net of tax (3,919 ) (8,532 ) Net loss (13,340 ) (15,724 ) ​ ​ ​ Weighted average common shares outstanding used in computing basic loss per share 45,626 56,709 Weighted average common shares outstanding used in computing diluted loss per share 45,626 56,709 ​ ​ ​ Basic net loss per share: Loss from continuing operations $ (0.21 ) $ (0.13 ) Loss from discontinued operations, net of tax (0.09 ) (0.15 ) Basic net loss per share $ (0.29 ) $ (0.28 ) ​ ​ ​ Diluted net loss per share: Loss from continuing operations $ (0.21 ) $ (0.13 ) Loss from discontinued operations, net of tax (0.09 ) (0.15 ) Diluted net loss per share $ (0.29 ) $ (0.28 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended December 31, 2024 2023 Time-based restricted stock units 87,117 62,983 Performance-based restricted stock units — 23,671 Employee stock purchase plan — 6,451 87,117 93,105

Note 15 - Segment and Geograp_2

Note 15 - Segment and Geographic Information (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	​ Three Months Ended December 31, ​ 2024 2023 Revenue: ​ Sample Management Solutions $ 81,213 $ 79,005 Multiomics 66,297 62,720 Total revenue $ 147,510 $ 141,725 ​ ​ ​ Adjusted operating income (loss): ​ ​ Sample Management Solutions $ 2,317 $ (616 ) Multiomics (2,503 ) (3,263 ) Segment adjusted operating loss (186 ) (3,879 ) ​ ​ ​ Amortization of completed technology 1,500 1,856 Amortization of intangible assets other than completed technology 4,573 5,371 Transformation costs (1) 3,046 41 Restructuring charges 431 786 Merger and acquisition costs and costs related to share repurchase (2) 1,570 4,321 Other unallocated corporate expenses 47 (9 ) Total operating loss (11,353 ) (16,245 ) Interest income, net 4,298 9,955 Other income, net 1,203 518 Loss before income taxes $ (5,852 ) $ (5,772 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Assets: December 31, 2024 September 30, 2024 Sample Management Solutions $ 840,580 $ 859,353 Multiomics 454,958 462,825 Total assets $ 1,295,538 $ 1,322,178 ​ December 31, September 30, ​ 2024 2024 Segment assets $ 1,295,538 $ 1,322,178 Cash and cash equivalents, restricted cash and marketable securities 501,277 490,707 Deferred tax assets 627 837 General corporate assets 12,591 23,631 Assets held for sale 231,177 262,688 Total assets $ 2,041,210 $ 2,100,041
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	​ Three Months Ended December 31, ​ 2024 2023 Geographic Location: ​ ​ United States $ 93,469 $ 90,127 China 14,888 14,898 United Kingdom 7,798 5,676 Rest of Europe 24,319 22,731 Asia Pacific/Other 7,036 8,293 Total revenue $ 147,510 $ 141,725

Note 1 - Nature of Operations (

Note 1 - Nature of Operations (Details Textual) $ in Millions	Dec. 31, 2024 USD ($)
Loss Contingency Accrual	$ 1.7

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Realized Gain (Loss), Foreign Currency Transaction, before Tax	$ 0.5	$ (0.5)

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Inventories	$ (4,646)	$ 4,929
Accounts payable	(2,602)	2,442
Other assets and liabilities	11,056	3,910
Net cash provided by operating activities	30,628	13,756
Purchases of property, plant and equipment	(8,580)	(11,291)
Net cash provided by investing activities	76,256	99,025
Effects of exchange rate changes on cash, cash equivalents and restricted cash	(8,311)	24,548
Purchases of property, plant and equipment included in accounts payable and accrued expenses	$ 3,249	2,164
Previously Reported [Member]
Inventories		4,542
Accounts payable		3,457
Other assets and liabilities		15,957
Net cash provided by operating activities		26,431
Purchases of property, plant and equipment		(11,919)
Net cash provided by investing activities		98,397
Effects of exchange rate changes on cash, cash equivalents and restricted cash		12,501
Purchases of property, plant and equipment included in accounts payable and accrued expenses		0
Revision of Prior Period, Adjustment [Member]
Inventories		387
Accounts payable		(1,015)
Other assets and liabilities		(12,047)
Net cash provided by operating activities		(12,675)
Purchases of property, plant and equipment		628
Net cash provided by investing activities		628
Effects of exchange rate changes on cash, cash equivalents and restricted cash		12,047
Purchases of property, plant and equipment included in accounts payable and accrued expenses		$ 2,164

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($) $ in Millions			1 Months Ended		3 Months Ended
	Feb. 01, 2022	Jul. 01, 2019	Apr. 30, 2023	Jan. 31, 2023	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2020
Loss Contingency Accrual						$ 1.7
Edwards Vacuum LLC Warranty Claim [Member]
Loss Contingency, Damages Sought, Value				$ 1
Loss Contingency Accrual							$ 2.5
Edwards Vacuum LLC Warranty Claim [Member] | Settled Litigation [Member]
Loss Contingency Accrual, Payments			$ 0.8		$ 0.8
Edwards Vacuum LLC Warranty Claim [Member] | Settled Litigation [Member] | Indemnification Agreement [Member]
Loss Contingency, Receivable, Proceeds			$ 1
Discontinued Operations, Disposed of by Sale [Member] | Semiconductor Automation Business [Member]
Proceeds from Divestiture of Businesses	$ 2,900
Discontinued Operations, Disposed of by Sale [Member] | Semiconductor Cryogenics Business [Member]
Proceeds from Divestiture of Businesses		$ 659.8

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Schedule of Disposal Groups (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Loss from discontinued operations, net of tax	$ (3,919)	$ (8,532)
B Medical Systems Business [Member] | Discontinued Operations, Held-for-Sale [Member]
Disposal group, revenue	17,591	12,592
Disposal group, cost of revenue	14,728	12,824
Gross profit	2,863	(232)
Research and development	1,635	1,180
Selling, general and administrative	6,187	8,687
Restructuring charges	314	334
Total operating expenses	8,136	10,201
Operating loss	(5,273)	(10,433)
Interest income, net	5	127
Other income, net	530	164
Loss before income taxes	(4,738)	(10,142)
Income tax benefit	(819)	(1,610)
Loss from discontinued operations, net of tax	(3,919)	(8,532)
Product [Member] | B Medical Systems Business [Member] | Discontinued Operations, Held-for-Sale [Member]
Disposal group, revenue	14,288	9,686
Disposal group, cost of revenue	11,422	10,056
Service [Member] | B Medical Systems Business [Member] | Discontinued Operations, Held-for-Sale [Member]
Disposal group, revenue	3,303	2,906
Disposal group, cost of revenue	$ 3,306	$ 2,768

Note 3 - Discontinued Operati_5

Note 3 - Discontinued Operations - Schedule of Disposal Groups - Non-cash Items (Details) - B Medical Systems Business [Member] - Discontinued Operations, Held-for-Sale [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Depreciation and amortization	$ 3,846	$ 7,219
Capital expenditures	$ 757	$ 1,246

Note 3 - Discontinued Operati_6

Note 3 - Discontinued Operations - Schedule of Disposal Groups - Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Cash included in current assets held for sale	$ 26,544	$ 30,899
Current assets held for sale	72,573	88,894
Noncurrent assets held for sale	158,604	173,794
Current liabilities held for sale	23,602	30,050
Noncurrent liabilities held for sale	38,131	42,196
B Medical Systems Business [Member] | Discontinued Operations, Held-for-Sale [Member]
Cash included in current assets held for sale	26,544	30,899
Accounts receivable, net	8,010	16,438
Inventories	33,361	36,333
Prepaid expenses and other current assets	4,658	5,224
Current assets held for sale	72,573	88,894
Property, plant and equipment, net	43,681	47,032
Intangibles, net	111,569	122,988
Other assets	3,354	3,774
Noncurrent assets held for sale	158,604	173,794
Accounts payable	9,148	11,089
Deferred revenue	598	1,485
Accrued warranty and retrofit costs	4,764	4,916
Accrued compensation and benefits	2,303	2,929
Accrued income taxes	1,840	4,012
Accrued expenses and other current liabilities	4,949	5,619
Current liabilities held for sale	23,602	30,050
Long-term deferred tax liabilities	32,802	36,093
Long-term operating lease liabilities	1,993	2,109
Other long-term liabilities	3,336	3,994
Noncurrent liabilities held for sale	$ 38,131	$ 42,196

Note 4 - Marketable Securitie_2

Note 4 - Marketable Securities (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale	$ 125,590	$ 110,316

Note 4 - Marketable Securitie_3

Note 4 - Marketable Securities - Reconciliation of Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Amortized cost	$ 113,580	$ 200,951
Gross unrealized losses	(205)	(387)
Gross unrealized gains	9	52
Fair value	113,384	200,616
US Treasury and Government [Member]
Amortized cost	68,189	118,159
Gross unrealized losses	(83)	(119)
Gross unrealized gains	9	51
Fair value	68,115	118,091
Certificates of Deposit [Member]
Amortized cost	2,229	5,212
Gross unrealized losses	(6)	(13)
Gross unrealized gains	0	1
Fair value	2,223	5,200
Corporate Debt Securities [Member]
Amortized cost	42,634	77,580
Gross unrealized losses	(116)	(255)
Gross unrealized gains	0	0
Fair value	42,518	$ 77,325
US States and Political Subdivisions Debt Securities [Member]
Amortized cost	528
Gross unrealized losses	0
Gross unrealized gains	0
Fair value	$ 528

Note 4 - Marketable Securitie_4

Note 4 - Marketable Securities - Schedule of Contractual Maturity (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Due in one year or less, amortized cost	$ 86,122
Due in one year or less, fair value	85,951
Due after one year through five years, amortized cost	23,880
Due after one year through five years, fair value	23,855
Due after ten years, amortized cost	3,578
Due after ten years, fair value	3,578
Total marketable securities, amortized cost	113,580
Total marketable securities, fair value	$ 113,384

Note 5 - Derivative Instrumen_3

Note 5 - Derivative Instruments (Details Textual) - Designated as Hedging Instrument [Member] $ in Thousands, € in Millions			3 Months Ended
	Feb. 03, 2025 USD ($)	Feb. 01, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Feb. 03, 2025 EUR (€)	Sep. 30, 2024 USD ($)	Feb. 01, 2024 EUR (€)	Feb. 01, 2023 USD ($)	Feb. 01, 2023 EUR (€)
Cross Currency Swap 2 [Member]
Derivative, Notional Amount		$ 436,000					€ 400	$ 436,000	€ 400
Derivative, Variable Interest Rate								1.66%	1.66%
Derivative, Forward Exchange Rate		1.09					1.09
Gain on Derivative Instruments, Pretax		$ 1,400
Cross Currency Swap 3 [Member]
Derivative, Notional Amount		$ 76,000					€ 70
Derivative, Variable Interest Rate		1.44%					1.44%
Cross Currency Swap 3 [Member] | Subsequent Event [Member]
Derivative, Notional Amount	$ 73,000				€ 70
Derivative, Forward Exchange Rate	1.0419				1.0419
Gain on Derivative Instruments, Pretax	$ 3,000
Cross Currency Swap 4 [Member] | Subsequent Event [Member]
Derivative, Notional Amount	$ 260,000				€ 250
Derivative, Variable Interest Rate	1.80%				1.80%
Cross Currency Interest Rate Contract [Member]
Derivative, Notional Amount			$ 75,978			$ 75,978
Interest Income, Other			$ 300	$ 1,800

Note 5 - Derivative Instrumen_4

Note 5 - Derivative Instruments - Schedule of Gain (Loss) on Derivatives (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Realized gains (losses) on derivatives not designated as hedging instruments	$ 1,195	$ (1,239)

Note 5 - Derivative Instrumen_5

Note 5 - Derivative Instruments - Schedule of Derivative Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Cross Currency Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Notional amount	$ 75,978	$ 75,978
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Notional amount	$ 36,573	$ 60,101

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Amortization of Intangible Assets	$ 6.1	$ 7.2

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets - Schedule of Goodwill (Details) $ in Thousands	3 Months Ended
	Dec. 31, 2024 USD ($)
Balance	$ 691,409
Currency translation adjustments	(18,503)
Balance	672,906
Sample Management Solutions [Member]
Balance	494,649
Currency translation adjustments	(18,503)
Balance	476,146
Multiomics [Member]
Balance	196,760
Currency translation adjustments	0
Balance	$ 196,760

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Intangibles assets, net	$ 115,822	$ 125,042
Patents [Member]
Intangibles assets, cost	1,220	1,227
Intangibles assets, accumulated amortization	1,220	1,227
Intangibles assets, net	0	0
Developed Technology Rights [Member]
Intangibles assets, cost	106,665	109,949
Intangibles assets, accumulated amortization	56,034	55,191
Intangibles assets, net	50,631	54,758
Trademarks and Trade Names [Member]
Intangibles assets, cost	705	726
Intangibles assets, accumulated amortization	214	195
Intangibles assets, net	491	531
Noncompete Agreements [Member]
Intangibles assets, cost	243,930	248,036
Intangibles assets, accumulated amortization	179,230	178,283
Intangibles assets, net	64,700	69,753
Other Intangible Assets [Member]
Intangibles assets, cost	352,520	359,938
Intangibles assets, accumulated amortization	236,698	234,896
Intangibles assets, net	$ 115,822	$ 125,042

Note 6 - Goodwill and Intangi_6

Note 6 - Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Remainder of fiscal year 2025	$ 18,243
2026	21,697
2027	17,290
2028	14,459
2029	11,854
2030	$ 10,336

Note 7 - Restructuring (Details

Note 7 - Restructuring (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Restructuring Charges	$ 431	$ 786
Sample Management Solutions [Member]
Restructuring Charges	200
Multiomics [Member]
Restructuring Charges	100
Corporate Segment [Member]
Restructuring Charges	$ 100

Note 7 - Restructuring - Schedu

Note 7 - Restructuring - Schedule of Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Severance and related costs	$ 320	$ 786
Other	111	0
Total restructuring charges	$ 431	$ 786

Note 7 - Restructuring - Sche_2

Note 7 - Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Provisions	$ 431	$ 786
Employee Severance [Member]
Balance at beginning of period	755	665
Provisions	320	786
Payments	(858)	(696)
Balance at end of period	$ 217	$ 755

Note 8 - Supplementary Balanc_3

Note 8 - Supplementary Balance Sheet Information (Details Textual) - USD ($) $ in Millions	Dec. 31, 2024	Sep. 30, 2024
Inventory Valuation Reserves	$ 7.2	$ 6.1

Note 8 - Supplementary Balanc_4

Note 8 - Supplementary Balance Sheet Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Raw materials and purchased parts	$ 39,916	$ 34,134
Work-in-process	7,585	8,402
Finished goods	33,505	36,387
Total inventories	$ 81,006	$ 78,923

Note 8 - Supplementary Balanc_5

Note 8 - Supplementary Balance Sheet Information - Schedule of Warranty and Retrofit Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Balance at beginning of period	$ 5,213	$ 3,974
Accruals for warranties during the period	187	903
Costs incurred during the period	(427)	(320)
Balance at end of period	$ 4,973	$ 4,557

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		23 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Nov. 04, 2022
Payment, Excise Tax for Repurchased Shares	$ 4,911	$ 0
Sales and Excise Tax Payable	$ 6,500
Share Repurchase Program November 2022 [Member]
Share Repurchase Program, Authorized, Amount				$ 1,500,000
Stock Repurchased During Period, Shares (in shares)	0	2,300
Stock Repurchased During Period, Value		$ 112,900
Stock Repurchased and Retired During Period, Shares (in shares)			30,000
Stock Repurchased and Retired During Period, Value			$ 1,500,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Balance	$ 1,768,967	$ 2,534,500
Balance	1,718,966	2,443,664
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(34,170)	(88,448)
Other comprehensive income (loss) before reclassifications	(47,298)	46,494
Amounts reclassified from accumulated other comprehensive loss	0	0
Balance	(81,468)	(41,954)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Balance	(263)	(5,135)
Other comprehensive income (loss) before reclassifications	163	2,524
Amounts reclassified from accumulated other comprehensive loss	0	0
Balance	(100)	(2,611)
AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]
Balance	21,468	31,487
Other comprehensive income (loss) before reclassifications	5,412	(13,368)
Amounts reclassified from accumulated other comprehensive loss	0	0
Balance	26,880	18,119
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	(499)	(330)
Other comprehensive income (loss) before reclassifications	(68)	(35)
Amounts reclassified from accumulated other comprehensive loss	18	27
Balance	(549)	(338)
AOCI Attributable to Parent [Member]
Balance	(13,464)	(62,426)
Other comprehensive income (loss) before reclassifications	(41,791)	35,615
Amounts reclassified from accumulated other comprehensive loss	18	27
Balance	$ (55,237)	$ (26,784)

Note 10 - Revenue From Contra_3

Note 10 - Revenue From Contracts with Customers (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024
Accounts Receivable, after Allowance for Credit Loss, Current	$ 155,038		$ 156,273
Contract with Customer, Asset, after Allowance for Credit Loss, Current	34,300		28,900
Contract with Customer, Asset, Revenue Recognized	9,200	$ 9,100
Contract with Customer, Liability	41,800		$ 30,500
Contract with Customer, Liability, Revenue Recognized	14,400	$ 21,600
Revenue, Remaining Performance Obligation, Amount	$ 84,556

Note 10 - Revenue From Contra_4

Note 10 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Total revenue		$ 147,510	$ 141,725
Multiomics [Member]
Total revenue		66,297	62,720
Core Products [Member]
Total revenue	[1]	49,699	48,886
Sample Repository Solutions [Member]
Total revenue		$ 31,514	$ 30,119
[1]Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, Consumables and Instruments and Controlled Rate Thawing Devices.

Note 10 - Revenue From Contra_5

Note 10 - Revenue From Contracts With Customers - Remaining Performance Obligations (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Remaining performance obligations	$ 84,556

Note 10 - Revenue From Contra_6

Note 10 - Revenue From Contracts With Customers - Remaining Performance Obligations 2 (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Remaining performance obligations	$ 84,556
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Remaining performance obligations	54,503
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01
Remaining performance obligations	$ 30,053

Note 10 - Revenue From Contra_7

Note 10 - Revenue From Contracts With Customers - Remaining Performance Obligations (Details) (Parentheticals)	Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Remaining performance obligations, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01
Remaining performance obligations, period (Year)	2 years

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2024	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Expense		$ 4,872	$ 3,001
Market Condition Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expense		$ 4,615	2,649
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		121,804,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 34,800
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 10 months 24 days
Time Based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Time Based Restricted Stock Units [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage		33.33%
Performance Based Restricted Stock Units [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 3,800
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Awards, Percentage Earned if Goals Met		100%
Share-Based Payment Arrangement, Plan Modification, Incremental Cost		$ 600
Performance Based Restricted Stock Units [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Awards, Percentage Earned if Goals Met		200%
Discontinued Operations [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		9,209
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)		31,475
Continuing Operations [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 4,700	7,200
Equity Incentive Plan 2020 [Member] | Discontinued Operations [Member]
Share-Based Payment Arrangement, Expense		$ 200	$ 200

Note 11 - Stock Based Compensat

Note 11 - Stock Based Compensation - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Total stock-based compensation expense	$ 4,872	$ 3,001
Restricted Stock Units (RSUs) [Member]
Total stock-based compensation expense	4,615	2,649
Employee Stock Purchase Plan [Member]
Total stock-based compensation expense	$ 257	$ 352

Note 11 - Stock Based Compens_2

Note 11 - Stock Based Compensation - Restricted Stock Unit Activity (Details) - $ / shares shares in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Time Based Restricted Stock Units [Member]
Granted (in shares)	364,173	199,316
Performance Based Restricted Stock Units [Member]
Granted (in shares)	155,689	388,532
Restricted Stock Units (RSUs) [Member]
Outstanding (in shares)	764,111
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 59.65
Granted (in shares)	519,862
Granted, weighted average grant-date fair value (in dollars per share)	$ 47.14
Vested (in shares)	(121,804)
Vested, weighted average grant-date fair value (in dollars per share)	$ 61.96
Forfeited (in shares)	(59,923)
Forfeited, weighted average grant-date fair value (in dollars per share)	$ 94.75
Outstanding (in shares)	1,102,246
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 51.21
Stock Awards and Restricted Stock Units [Member]
Granted (in shares)	519,862	587,848

Note 12 - Fair Value Measurem_3

Note 12 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands		3 Months Ended
	Oct. 02, 2024	Dec. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Nonrecurring [Member]
Asset Impairment Charges		$ 0		$ 0
Conversion from Convertible Notes to Preferred Stock, Principal and Interest [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	420,000
Convertible Debt Securities [Member] | Private Company [Member]
Payments to Acquire Equity Securities, FV-NI			$ 2,000
Equity Securities, FV-NI		$ 2,100

Note 12 - Fair Value Measurem_4

Note 12 - Fair Value Measurements - Schedule of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Available-for-sale debt securities	$ 113,384	$ 200,616
Fair Value, Recurring [Member]
Cash equivalents	207,170	157,990
Investment in equity securities	2,100
Foreign exchange contracts	35	9
Net investment hedge	3,497
Total assets	326,186	358,615
Foreign exchange contracts	122	213
Total liabilities	122	2,128
Net investment hedge, liability		1,915
Fair Value, Recurring [Member] | Excluding Convertible Debt Securities [Member]
Available-for-sale debt securities	113,384	198,616
Fair Value, Recurring [Member] | Convertible Debt Securities [Member]
Available-for-sale debt securities		2,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	200,395	157,990
Investment in equity securities	0
Foreign exchange contracts	0	0
Net investment hedge	0
Total assets	215,394	195,574
Foreign exchange contracts	0	0
Total liabilities	0	0
Net investment hedge, liability		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Excluding Convertible Debt Securities [Member]
Available-for-sale debt securities	14,999	37,584
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Convertible Debt Securities [Member]
Available-for-sale debt securities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	6,775	0
Investment in equity securities	0
Foreign exchange contracts	35	9
Net investment hedge	3,497
Total assets	108,692	161,041
Foreign exchange contracts	122	213
Total liabilities	122	2,128
Net investment hedge, liability		1,915
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Excluding Convertible Debt Securities [Member]
Available-for-sale debt securities	98,385	161,032
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Convertible Debt Securities [Member]
Available-for-sale debt securities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents	0	0
Investment in equity securities	2,100
Foreign exchange contracts	0	0
Net investment hedge	0
Total assets	2,100	2,000
Foreign exchange contracts	0	0
Total liabilities	0	0
Net investment hedge, liability		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Excluding Convertible Debt Securities [Member]
Available-for-sale debt securities	$ 0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Convertible Debt Securities [Member]
Available-for-sale debt securities		$ 2,000

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Expense (Benefit)	$ 3,569	$ 1,420
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount		500
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount		$ 600
Open Tax Year	2018 2019 2020 2021 2022 2023 2024 2025
Domestic Tax Jurisdiction [Member]
Deferred Tax Assets, Valuation Allowance	$ 11,900

Note 14 - Net Loss Per Share -

Note 14 - Net Loss Per Share - Schedule Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Loss from continuing operations	$ (9,421)	$ (7,192)
Loss from discontinued operations, net of tax	(3,919)	(8,532)
Net loss	$ (13,340)	$ (15,724)
Weighted average common shares outstanding used in computing basic loss per share (in shares)	45,626	56,709
Weighted average common shares outstanding used in computing diluted loss per share (in shares)	45,626	56,709
Loss from continuing operations (in dollars per share)	$ (0.21)	$ (0.13)
Loss from discontinued operations, net of tax (in dollars per share)	(0.09)	(0.15)
Basic net loss per share (in dollars per share)	(0.29)	(0.28)
Loss from continuing operations (in dollars per share)	(0.21)	(0.13)
Loss from discontinued operations, net of tax (in dollars per share)	(0.09)	(0.15)
Diluted net loss per share (in dollars per share)	$ (0.29)	$ (0.28)

Note 14 - Net Loss Per Share _2

Note 14 - Net Loss Per Share - Schedule of Dilutive Securities (Details) - shares	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Dilutive securities (in shares)	87,117	93,105
Time Based Restricted Stock Units [Member]
Dilutive securities (in shares)	87,117	62,983
Performance Based Restricted Stock Units [Member]
Dilutive securities (in shares)		23,671
Employee Stock Purchase Plan [Member]
Dilutive securities (in shares)		6,451

Note 15 - Segment and Geograp_3

Note 15 - Segment and Geographic Information (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024
Revenue Benchmark [Member]
Major Customers	0	0
Accounts Receivable [Member]
Major Customers			0
Accounts Receivable [Member] | Sample Management Solutions [Member]
Major Customers	1

Note 15 - Segment and Geograp_4

Note 15 - Segment and Geographic Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Total revenue		$ 147,510	$ 141,725
Segment adjusted operating income (loss)		(11,353)	(16,245)
Amortization of intangible assets		6,100	7,200
Transformation costs (1)	[1]	3,046	41
Provisions		431	786
Merger and acquisition costs and costs related to share repurchase (2)	[2]	1,570	4,321
Interest income, net		4,298	9,955
Other income, net		1,203	518
Loss before income taxes		(5,852)	(5,772)
Developed Technology Rights [Member]
Amortization of intangible assets		1,500	1,856
Other Intangible Assets [Member]
Amortization of intangible assets		4,573	5,371
Operating Segments [Member]
Segment adjusted operating income (loss)		(186)	(3,879)
Sample Management Solutions [Member]
Total revenue		81,213	79,005
Provisions		200
Sample Management Solutions [Member] | Operating Segments [Member]
Segment adjusted operating income (loss)		2,317	(616)
Multiomics [Member]
Total revenue		66,297	62,720
Provisions		100
Multiomics [Member] | Operating Segments [Member]
Segment adjusted operating income (loss)		(2,503)	(3,263)
Corporate Segment [Member]
Provisions		100
Other unallocated corporate expenses		$ 47	$ (9)
[1]Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company’s operations, processes and systems to permanently alter the Company’s operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company’s 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.[2]Includes expenses related to governance-related matters.

Note 15 - Segment and Geograp_5

Note 15 - Segment and Geographic Information - Schedule of Segment Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Total assets	$ 2,041,210	$ 2,100,041
Cash and cash equivalents, restricted cash and marketable securities	501,277	490,707
Deferred tax assets	627	837
General corporate assets	12,591	23,631
Assets held for sale	231,177	262,688
Operating Segments [Member]
Total assets	1,295,538	1,322,178
Sample Management Solutions [Member] | Operating Segments [Member]
Total assets	840,580	859,353
Multiomics [Member] | Operating Segments [Member]
Total assets	$ 454,958	$ 462,825

Note 15 - Segment and Geograp_6

Note 15 - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Total revenue	$ 147,510	$ 141,725
UNITED STATES
Total revenue	93,469	90,127
CHINA
Total revenue	14,888	14,898
UNITED KINGDOM
Total revenue	7,798	5,676
Europe [Member]
Total revenue	24,319	22,731
Asia Pacific [Member]
Total revenue	$ 7,036	$ 8,293

Note 16 - Commitments and Con_2

Note 16 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jul. 31, 2024	Sep. 30, 2022	Dec. 31, 2024
Other Commitment			$ 50.1
Purchase Orders For Inventory [Member]
Other Commitment			36
Information Technology Related Commitments [Member]
Other Commitment			$ 14.1
Tariff Matter [Member]
Loss Contingency Accrual, Payments	$ 2.5	$ 5.9